GSK (GSK) said Thursday it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to Bharat Biotech for further development and potential distribution in low- and middle-income countries where Shigella is a leading cause of diarrheal disease in children.
The vaccine has shown promising results in early clinical trials and is designed to target the most common Shigella serotypes, the company said.
Bharat Biotech will lead late-stage development and large-scale manufacturing, with GSK supporting phase 3 trial design and helping secure external funding, GSK added.
The agreement aims to address Shigella's significant health burden in children under five and reduce antibiotic use, which could help combat antimicrobial resistance, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.